Soft tissue sarcomas (STS) are rare tumours, as they account for 0.7% of all malignant disease in adults. They represent an heterogeneous group of tumours which are histologically classified by their supposed histogenesis. At present, more than 60 types and subtypes are recognised (Enterline, 1981; Enzinger, 1983; Hadju, 1979) .
The main advances achieved in the management of STS have been in the field of local control, which can now be obtained in approximately 80% of cases, despite important remaining problems such as the treatment of particular locations -such as the head, neck and retroperitoneum -the respective value of radical surgery versus less than radical surgery plus radiotherapy (Enneking et al., 1981; Enneking 1983; Rosenberg et al., 1982) , optimal radiation therapy techniques Suit et al., 1985) , or the role of a preoperative treatment (Lagarde et al., 1988; Rouesse et al., 1987) . Therefore, one can consider that survival of patients with STS is mainly related to the metastatic risk of their disease. However, this metastatic evolution is widely variable from one tumour to another even within a same tumour type.
Many prognostic classifications of STS have been developed according to different evaluation of prognostic variables (Enzinger, 1983; Hajdu, 1979; Russell et al., 1977) . The AJC system is the most widely used, but was established by a retrospective study, and whether this system is predictive in contemporary patients remains questionable (Presant et al., 1986; Russell et al., 1977) . Moreover, the predictive value of this classification for metastatic recurrences in the particular group of operable patients is unclear. Therefore, its suitability in selecting poor risk patients to whom adjuvant chemotherapy could be given has not been assessed.
This study was undertaken in a series of patients referred for their first treatment to one institution and managed with an homogeneous strategy for local treatment and without adjuvant chemotherapy. Only operable patients were considered to determine the poor prognostic group to be eventually selected for adjuvant treatment (Bui et al., 1989; Ravaud et al., 1990 ).
Patients and methods
Patient selection From 1975 to 1988, 381 patients were referred to Fondation Bergonie (FB) for STS proven by a systematic histological review. Visceral sarcomas were not considered here. Fortyone presented with overt metastatic disease, 123 had a local recurrence after a previous treatment outside FB. The remaining 217 patients were referred for a non-metastatic and until then untreated primary. In 32 patients, a preoperative chemotherapy was performed. Moreover, 44 patients received adjuvant chemotherapy after resection of their primary; these patients were excluded. The remaining 141 patients were considered for this study because they were those for whom an adjuvant chemotherapy could prove effective, as they were: (1) naive of treatment, (2) primarily treated by surgery, (3) treated and followed at a single institution, (4) without adjuvant or neoadjuvant chemotherapy. (Trojani et al., 1984; Coindre et al., 1986) . For statistical analysis evaluating Hadju's classification, grade was defined as low with FNCLCC total grading scores from 2 to 4 and as high with FNCLCC total grading scores from 5 to 8. Tumours from all sites were considered providing a tumour excision was done primarily. Extremity tumours were subsequently divided into proximal or distal tumours at analysis. Tumours of trunk wall and those from deeper locations, such as the retroperitoneum, pelvis or mediastinum were analysed separately. Tumour size was defined as the largest tumour diameter measured either on CAT scan or on the excised specimen. A tumour situated beneath or involving the superficial fascia was considered as deep, and a tumour above the fascia as superficial. According to these characteristics, the tumours were classified according to both AJC/ UICC and Hajdu's classifications.
Patients
Of the 141 patients, there were 77 males and 64 females, aged from 16 to 87 with a median of 50.3 years. The primary tumours were located in head and neck in 14 patients, proximal extremities in 52, distal extremities in 29, mediastinum, retroperitoneum or pelvis in 22, trunk wall including limb girdles in 24. Tumour size was less than 5 cm in only 47 patients and equal to or larger than 5 cm in 88. Forty tumours were superficial and 99 were deep. Gross or microscopic invasion of neurovascular structures or bone was present in 17 patients. Histologic types are listed in Table I Surgery was the first treatment in all patients. The policy was to drastically limit amputations to patients with a major osseous or vasculonervous involvement considered inaccessible to 'en-bloc' resection. Compartmental surgery was not used. Wide resection, consisting of an excision of the tumour and the biopsy scar with a margin of a few centimeters of macroscopically normal tissue, was used whenever possible. Marginal resection was defined as an operation in which this margin of normal tissue could not be obtained at every point on the tumour periphery, owing either to tumour location or to the need to preserve a major vasculonervous axis or bone, adherent to the tumour but not macroscopically involved. Regional lymph node dissection was performed only in patients with an involvement proven by cytologic examination of a suspect node. For patients referred after tumour removal elsewhere, decision for reexcision was considered for each case, after clinical and radiological reevaluation of the local status, and after discussion with patients and referring physicians. However, reexcision was systematic in patients addressed 30 days or more after the initial surgery.
Consequently, the surgical procedures were amputation for only five patients, marginal resection in 64, and wide resection in 72. For seven patients, macroscopic tumour residues were left. Follow-up and statistics Follow-up consisted in clinical examination with chest X-ray every 2 months for 2 years, then every 4 months for 3 years, then every year. Abdominal ultrasonography were also performed in patients with intraperitoneal and abdominal tumours. Relapse or metastases was documented by biopsy or unequivocal radiographic findings. No patient was lost for follow-up. Survival, disease-free survival, and local or metastatic recurrence-free survival were computed by the Kaplan Meier method (Kaplan, 1958) . The initiation of treatment was considered as the time of origin. Death whatever the cause was considered as the event for overall survival studies, recurrence (local and/or metastatic) for disease-free survival, local recurrence for local recurrencefree survival and metastatic recurrence for metastasis-free survival.
For each variable in the univariate analysis, we used either the log-rank test (Peto, 1972) when two modalities of the variable were compared, or a test for trend (Peto, 1977 ) when three modalities were tested. Each variable was studied for each of the following end points: local recurrence, metastatic recurrence and overall survival. The variables, with P value <0.10 in the univariate analysis, were included in Cox's models (Cox, 1972) This defined score makes it possible to rank each patient on a scale with an increasing risk. Score values may be delimited to determine different prognostic groups.
Results
With a median follow-up of 57.6 months (range 11-168 months), 11 patients (7.8%) died from a cause unrelated to the treated sarcoma: cardiac or vascular disease: four; cerebral palsy: one, pulmonary infection: one; diabetes mellitus: one; suicide: one; other cancer: three (osteosarcoma, colon cancer, renal cancer); three of these patients presented a local recurrence and one a metastatic spread. These patients were excluded from the overall survival analysis but not from disease-free or metastasis-free survival evaluations. At their last follow-up visit, 90 patients were alive without evidence of disease (63.8%), six were alive with recurrence (4.3%), 34 had died from STS (24.1%); for the entire series, the actuarial 5-year overall survival rate was 66.1% ( Figure 1) ; the disease-free 5-year survival rate was 51.4% ( Figure 1) ; the metastasis-free 5-year survival rate was 63.2% (Figure 2 ) and the local recurrence-free 5-year survival rate was 73.1% ( Figure 2 ).
Univanate analysis (Table II) Age and sex did not affect patient evolution, although there was a trend for a better local recurrence-free survival in male patients (P = 0.06). Tumour size The median largest tumour diameter in this series was 8.2 cm (range 1-40 cm). Patients with tumours less than 5 cm had a significantly better overall survival (P = 0.01), disease-free survival (P = 0.006) and metastasis-free survival (P = 0.03) than those with a tumour of 5 cm or more. There was no significant difference in terms of local recurrence-free survival (P = 0.14).
Invasion of neurovascular structures or bone Patients with such an invasion had a significantly worse prognostic in overall survival (P = 0.003), disease-free survival (P = 0.003) and metastasis-free survival (P = 0.007) than those without invasion.
T staging Owing to differences according to tumour size and local invasion, there was a significant difference in evolution between T1, T2, T3 lesions, as defined by the AJC staging system, except for local recurrence-free survival.
Tumour depth Tumour depth had a significant impact on prognostic. Patients with superficial lesions had a significantly better overall survival (P = 0.003) (Figure 3) , disease- :,,.,,~----- lower overall survival (P < 0.0001), disease-free survival (P <0.0001) and metastasis-free survival (P = 0.04).
AJC/UICC classification Prognostic groups established according to tumour size, local tumour invasiveness, tumour grade, and node status according to the AJC/UICC classification were predictive for overall survival (Figure 7) , metastasis-free survival (Figure 8 ) and disease-free survival. There was no significant difference between stage III and stage IVa, but this latter subgroup is poorly represented in this study owing to patient selection. The AJC/UICC appears to be more discriminating for prognostic evaluation than Hajdu's classification, which considers tumour size, grade and depth, where no significant difference appeared between stage 0, I or II. However, there was a significant difference in overall survival (P = 0.0006), disease-free survival (P = 0.0007) and metastasis-free survival (P = 0.0001) between stages II and III.
Multivanate analysis (Tables III, IV, V, VI) The six prognostic variables (tumour site, tumour size, tumour depth, invasion of neurovascular structures or bone, grade and macroscopic margins) found to be significantly correlated with evolution in univariate analysis were selected for a Cox's stepwise multivariate analysis. This analysis was done in 131 patients with no missing data. Tumour grade, and tumour depth was the most significant predictive variables for metastasis-free survival (Table III) . Furthermore, these two variables and tumour site were predictive factors for overall survival (Table IV) . On the other hand, macroscopic margins and sex were significant for local recurrence (Table VI) .
According to the end points considered in this study, each patient with STS could be scored for MFS and OS, considering the coefficient value of each significant variable determined by Cox's multivariate analysis (Table III, V) . (Elias, 1989; Ravaud et al., 1990) . Among the reasons which can be called upon to explain the discrepancies in results from the different clinical trials performed, there is the difference in the selection of poor risk patients, owing to differences in evaluation of prognostic variables (Coindre et al., 1986; Collin et al., 1987; Costa et al., 1984; Enzinger, 1983; Hajdu, 1979; Heise et al., 1986; Lack et al., 1989; Mandard et al., 1989; Markhede et al., 1982; Potter et al., 1986; Presant et al., 1986; Russel, 1977; Shiraki et al., 1989; Stotter et al., 1990; Trojani et al., 1984; Ueda et al., 1988) . This study confirms that the evolution of patients with an operable STS depends mainly on the eventual advent of metastatic disease: of the 34 patients who died from sarcoma, death was due to a metastatic spread in 30/34 patients (88.3%) and only 4/34 patients (11.3%) died of local tumour evolution. Therefore, the main end point to define high-risk patients must be metastasis-free survival rather than overall survival or disease-free survival. In this study, the prognostic variables which confer the highest relative risk for metastatic disease were tumour grade and tumour depth. These variables have also been found of prognostic importance in previous studies, although dealing with other patient selection criteria (Trojani et al., 1984) .
In this series, tumour location (limb tumours versus nonlimb tumours) had an impact only on overall survival. The only point which could explain the difference in overall survival, while no significant difference in local recurrence and metastatic rate was found, was a better outcome following rescue treatments in patients with an extremity tumour who experienced a local relapse. That may also be due in part to the patient selection modalities used to allow a primarily conservative surgery. Patients who did not fit those selection criteria were included in another treatment program with systematic neoadjuvant chemotherapy; among those patients, 62% had non-limb tumours (Ravaud et al., 1990) .
Previous studies have pointed out other significant prognostic variables such as tumour size, invasion of adjacent neurovascular structures or bone, histopathological types and surgical margins.
In this series as in others (Collin et al., 1987; Heise et al., 1986; Lack et al., 1989; Markhede et al., 1982; Potter et al., 1986; Trojani et al., 1984) tumour histopathological type was difficult to correlate with prognostic, although better prognostic was associated with certain types, while others like synovial sarcoma or undifferentiated sarcoma were more ominous. However, the rarity of sarcomas and the multiplicity of tumour types and subtypes lead to considerable difficulty in pathological classification (Coindre et al., 1986; Presant et al., 1986; Shiraki et al., 1989) . Moreover, as results of tumour histopathological classification are highly variable from one pathologist to another, a prognostic evaluation based on tumour type appears hazardous. In fact, histopathological type has already been reported to be less predictive of the evolution of sarcoma than tumour grade (Markhede et al., 1982) .
In this series as in others (Coindre et al., 1986; Collin et al., 1987; Costa et al., 1984; Enzinger, 1983; Hajdu, 1979; Heise et al., 1986; Lack et al., 1989; Mandard et al., 1989; Markhede et al., 1982; Potter et al., 1986; Presant et al., 1986; Russell, 1977; Shiraki et al., 1989; Stotter et al., 1990; Trojani et al., 1984; Ueda et al., 1988) , tumour grade was found to be the most important single prognostic variable correlated with survival and metastasisfree survival. However, grading of STS can be done by various means (Coindre et al., 1986; Costa et al., 1985; Enzinger, 1983; Hajdu, 1979; Russell, 1977; Trojani et al., 1984) , and this can result in discrepancies in the resulting grades (Coindre et al., 1986; Mandard et al., 1989) . Therefore, with the prognostic importance devoted to this variable in STS, it is necessary to establish a consensus on sarcoma grading. Among the other prognostic variables, tumour depth was the only clinical prognostic variable selected by the multivariate analysis in this study. The importance of this variable has been pointed out by Hadju (1977) . However, the present study considers evaluation of these prognostic variables according to Hadju's classification and found poor discrimination between intermediate and good prognostic groups.
Other variables which are used in the AJC/UICC staging system were predictive in overall survival and metastasis-free survival but were not found significant by multivariate analysis. Once again, this may be due mainly to patient selection for this series, with patients with T3 tumours or the largest tumours being preferably treated with chemotherapy before surgery in our institution. Therefore, the latter patients are under represented with only 17 patients with a vascular or bone involvement. Moreover node involvement is known to result in poor prognostic (Bui et al., 1987; Russell et al., 1977 ), but is rare at presentation in STS; only one patient had such an initial node involvement in this series which excluded patients presenting with a recurrence.
Despite these remarks, the AJC/UICC staging system has been found in this study to be predictive in overall survival and metastasis-free survival. However, analysis revealed a large prognostic disparity among patients especially for patients with intermediate outcome. Using tumor depth, it was possible to discriminate from among those patients with stage II disease, those with a grade 2 superficial tumour who had a low metastatic risk and an overall survival comparable to patients with grade 1 tumour and those with a deep tumour grade 2, who had a high metastatic risk and a prognostic similar to patients with grade 3 tumours.
Therefore, a prognostic combination of tumour depth with the variables of the AJC/UICC classification, was found to be useful for practical prognosis in STS patients. Those with a grade 3 tumour or a deep grade 2 lesion or a neurovascular or bone involvement have a high metastatic risk and poor outcome. They represent the population of sarcoma patients who should be considered for adjuvant chemotherapy trials (Elia et al., 1989; Ravaud et al., 1990) .
